Hennion & Walsh Asset Management Inc. Boosts Holdings in Altimmune, Inc. $ALT

Hennion & Walsh Asset Management Inc. grew its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 156.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 518,198 shares of the company’s stock after acquiring an additional 316,209 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.27% of Altimmune worth $1,575,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Arax Advisory Partners increased its holdings in Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after acquiring an additional 1,928 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Altimmune in the 1st quarter valued at approximately $50,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune during the 3rd quarter valued at approximately $38,000. Finally, BNP Paribas Financial Markets lifted its stake in Altimmune by 108.5% during the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALT has been the topic of several research reports. Leerink Partners assumed coverage on shares of Altimmune in a research note on Monday, June 22nd. They set an “outperform” rating and a $10.00 price objective on the stock. Citizens Jmp dropped their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Tuesday, June 2nd. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, HC Wainwright restated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.33.

Altimmune Stock Performance

Altimmune stock opened at $2.93 on Thursday. Altimmune, Inc. has a fifty-two week low of $2.56 and a fifty-two week high of $6.44. The firm’s 50 day simple moving average is $2.90 and its 200-day simple moving average is $3.42. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56. The company has a market cap of $569.80 million, a P/E ratio of -3.15 and a beta of 0.27.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. As a group, equities research analysts predict that Altimmune, Inc. will post -0.64 EPS for the current year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.